neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy offers a new delivery method for epinephrine in Canada for adults and children ( >30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects availability in the summer of 2026 SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, announced today that Health Canada has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) in…